-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1667 Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, adult, Lymphomas, non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, immune mechanism, real-world evidence, immunology, aggressive lymphoma, Lymphoid Malignancies, Biological Processes, Study Population, Human
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Alexandre Willaume, MD1*, Mourtaza Karimdjee, MD2*, Sandy Amorim, MD3*, Benjamin Carpentier, MD4*, Benedicte Hivert, MD5*, Emmanuelle Bourgeois-Petit, MD6*, Pierre Gosset, MD7*, Alban Bailliez, MD, PhD8* and Laurent Pascal, MD, PhD9*

1Université Catholique de Lille, Hôpital Saint Vincent de Paul, Lille, FRA
2Humanitep, Groupement des Hôpitaux Catholique de Lille, LOMME, France
3Hématologie clinique, Hôpital Saint Vincent de Paul, Lille, France
4Hopital Saint Vincent, GHICL, Lille, FRA
5Groupement des Hopitaux Institut Catholique de Lille, Lille, France
6Hematology, Hôpital Saint Vincent de Paul, Lille Cedex, FRA
7Hôpital Saint Vincent de Paul, Laboratoire d'Anatomo-Pathologie, Groupement des Hôpitaux Catholique de Lille, LILLE, France
8Hôpital Saint Philibert, Humanitep, Groupement des Hôpitaux Catholique de Lille, LOMME, France
9Université Catholique de Lille, Hopital Saint Vincent de Paul, Lille, FRA

BACKGROUND: Diffuse large cell B lymphoma (DLBCL) is the most common lymphoma in adults. The International Prognostic Index (IPI) has been used since 1993 to assess the severity of the disease. Other prognostic factors have emerged such as total metabolic tumor volume (TMTV) assessed by PET-CT and lymphopenia at diagnosis. The objective of our study was to evaluate the prognostic value of lymphopenia and TMTV in LDGCB in comparison with the IPI score.

METHOD: We constituted a retrospective monocentric cohort of patients treated with R-CHOP or R-ACVBP in 1st line of DLBCL. The TMTV on the initial PET-CT scan was acquired using an artificial intelligence module and was related to the patient volume measured on the scan (TMTV/PV ratio). The effect of prognostic factors on 3-year progression-free survival (PFS) and overall survival (OS) was analyzed by comparison of Kaplan-Meier curves (Log-Rank test) and Cox regression.

RESULTS : 118 patients with a lymphocyte count at diagnosis were included in the survival analysis. Among them, 53 patients underwent PET-CT analysis. Two factors were associated with decreased OS at 3 years: lymphocyte count at diagnosis ≤ 0.7G/L (76.9% vs 93.5%; p = 0.009) and TMTV/VP ratio > 0.35% (81% vs 96.9%; p = 0.05). The combination of these two factors was superior to the IPI score in discriminating patients' 3-year PFS (88.9% if no adverse factors, 55.6% if 1 factor, 12.5% if 2 factors present; p < 0.001).

CONCLUSION: Lymphopenia and elevated TMTV/VP ratio at the diagnosis of LDGCB are individually associated with decreased overall survival of patients. The combination of these two factors is superior to the IPI in our study to discriminate the 3-year progression-free survival of patients.

Disclosures: Pascal: Janssen: Consultancy; Gilead: Consultancy; Roche: Consultancy.

*signifies non-member of ASH